For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
To determine if adding the drug olaparib to the usual radiation therapy for inflammatory breast cancer will decrease the risk of cancer returning.
DiagnosisBreast cancer patients who have had surgery and whose cancer is diagnosed as inflammatory.
Must have completed chemotherapy before mastectomy, as well as the mastectomy, itself.
They may or may not have had chemotherapy after surgery.
Must be registered to the study at least 3 weeks, but no more than 12 weeks after mastectomy.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Olaparib (Lynparza®)
- Radiation Therapy
- Lab Biomarker Analysis
- ARM I: Olaparib 25mg BID + Standard Radiation Therapy
- ARM II: Radiation Therapy Alone
Patients will be followed every 3 months from start of study for the first 3 years, and then every 6 months until 8 years from start of study.
For more information, visit ClinicalTrials.gov